INO 5401

Drug Profile

INO 5401

Alternative Names: INO-5401

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Inovio Pharmaceuticals; Regeneron Pharmaceuticals
  • Class Antineoplastics; DNA; Immunotherapies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer; Glioblastoma

Most Recent Events

  • 16 Oct 2017 Phase-I/II clinical trials in Bladder cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) (Parenteral)
  • 16 Oct 2017 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Newly diagnosed) in USA (Parenteral)
  • 01 Jun 2017 Inovio Pharmaceuticals and Genentech enter into a collaboration to evaluate combination therapy of T cell immunotherapy and PD-L1 checkpoint inhibitor in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top